Agenus Inc. (NASDAQ:AGEN) Shares Purchased by Values First Advisors Inc.

Values First Advisors Inc. boosted its stake in Agenus Inc. (NASDAQ:AGEN) by 7.8% in the 4th quarter, Holdings Channel reports. The firm owned 269,829 shares of the biotechnology company’s stock after buying an additional 19,568 shares during the quarter. Values First Advisors Inc.’s holdings in Agenus were worth $223,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in AGEN. U.S. Capital Wealth Advisors LLC purchased a new position in Agenus in the 1st quarter valued at about $25,000. Commonwealth Equity Services LLC bought a new position in shares of Agenus during the third quarter worth about $26,000. Sei Investments Co. bought a new position in shares of Agenus during the first quarter worth about $28,000. SG Americas Securities LLC bought a new position in shares of Agenus during the third quarter worth about $36,000. Finally, Two Sigma Securities LLC lifted its position in shares of Agenus by 116.9% during the second quarter. Two Sigma Securities LLC now owns 22,750 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 12,263 shares during the last quarter. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Garo H. Armen bought 500,000 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were purchased at an average price of $0.65 per share, with a total value of $325,000.00. Following the completion of the acquisition, the insider now directly owns 625,969 shares in the company, valued at $406,879.85. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.80% of the stock is owned by corporate insiders.

Agenus Price Performance

NASDAQ:AGEN traded up $0.02 during midday trading on Thursday, hitting $0.58. 5,492,624 shares of the stock were exchanged, compared to its average volume of 10,264,015. Agenus Inc. has a one year low of $0.49 and a one year high of $2.13. The business has a 50-day moving average price of $0.65 and a two-hundred day moving average price of $0.80.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. StockNews.com raised shares of Agenus from a “sell” rating to a “hold” rating in a research report on Sunday. B. Riley cut their target price on shares of Agenus from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Monday, March 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Agenus in a report on Thursday, March 14th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Agenus currently has an average rating of “Moderate Buy” and an average price target of $7.10.

Agenus Profile

Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.